KR102599718B1 - 표적 엔티티 검출을 위한 시스템, 조성물 및 방법 - Google Patents

표적 엔티티 검출을 위한 시스템, 조성물 및 방법 Download PDF

Info

Publication number
KR102599718B1
KR102599718B1 KR1020217031580A KR20217031580A KR102599718B1 KR 102599718 B1 KR102599718 B1 KR 102599718B1 KR 1020217031580 A KR1020217031580 A KR 1020217031580A KR 20217031580 A KR20217031580 A KR 20217031580A KR 102599718 B1 KR102599718 B1 KR 102599718B1
Authority
KR
South Korea
Prior art keywords
delete delete
target
cancer
detection
entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217031580A
Other languages
English (en)
Korean (ko)
Other versions
KR20210141952A (ko
Inventor
조셉 찰스 세들락
로라 테레사 보톨린
다니엘 파커 세일럼
Original Assignee
메르시 바이오애널리틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르시 바이오애널리틱스, 인코포레이티드 filed Critical 메르시 바이오애널리틱스, 인코포레이티드
Publication of KR20210141952A publication Critical patent/KR20210141952A/ko
Application granted granted Critical
Publication of KR102599718B1 publication Critical patent/KR102599718B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020217031580A 2019-03-01 2020-02-28 표적 엔티티 검출을 위한 시스템, 조성물 및 방법 Active KR102599718B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812878P 2019-03-01 2019-03-01
US62/812,878 2019-03-01
US202062962722P 2020-01-17 2020-01-17
US62/962,722 2020-01-17
PCT/US2020/020529 WO2020180741A1 (en) 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection

Publications (2)

Publication Number Publication Date
KR20210141952A KR20210141952A (ko) 2021-11-23
KR102599718B1 true KR102599718B1 (ko) 2023-11-09

Family

ID=72338354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031580A Active KR102599718B1 (ko) 2019-03-01 2020-02-28 표적 엔티티 검출을 위한 시스템, 조성물 및 방법

Country Status (9)

Country Link
US (3) US11085089B2 (https=)
EP (2) EP3931351B1 (https=)
JP (1) JP7344973B2 (https=)
KR (1) KR102599718B1 (https=)
CN (1) CN113748217B (https=)
AU (2) AU2020233286B2 (https=)
CA (1) CA3129868A1 (https=)
SG (1) SG11202109423TA (https=)
WO (1) WO2020180741A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020233286B2 (en) 2019-03-01 2022-10-20 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
DE102020003794A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, Verwendung des Verfahrens sowle Kit zum Nachweis von Bioindikatoren in einer Probe
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4373975A4 (en) * 2021-07-21 2025-04-23 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR THE DETECTION OF PANCREATIC CANCER
US20250297317A1 (en) * 2021-07-21 2025-09-25 Mercy Bioanalytics, Inc. Compositions and methods for detection of liver cancer
WO2023004083A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of bile duct cancer
US20250043357A1 (en) * 2021-07-21 2025-02-06 Mercy Bioanalytics, Inc. Compositions and methods for detection of esophageal cancer
EP4373860A4 (en) * 2021-07-21 2025-05-21 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR THE DETECTION OF PROSTATE CANCER
EP4374172A4 (en) * 2021-07-21 2025-05-14 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR DETECTING BREAST CANCER
EP4374173A4 (en) * 2021-07-21 2026-02-25 Mercy Bioanalytics Inc CANCER COMPOSITIONS AND DETECTION METHODS
WO2023004077A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of colorectal cancer
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023091618A1 (en) * 2021-11-17 2023-05-25 Mercy Bioanalytics, Inc. Compositions and methods for detection of ovarian cancer
EP4623094A1 (en) * 2022-11-23 2025-10-01 Range Biotechnologies, Inc. Compositions and methods for detection of protein analytes
WO2025252658A1 (en) 2024-06-03 2025-12-11 Olink Proteomics Ab New product and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246792A1 (en) 1999-06-17 2009-10-01 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2015188192A3 (en) 2014-06-06 2016-05-26 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
WO2017214127A1 (en) 2016-06-06 2017-12-14 Redvault Biosciences, Lp Target reporter constructs and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795714A (en) * 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
CA2118759C (en) 1993-04-21 2004-06-22 William Jeffrey Allard Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US8013134B2 (en) 2001-11-23 2011-09-06 Olink Ab Kit for proximity probing with multivalent proximity probes
AU2004232976B2 (en) 2003-04-18 2011-02-10 Becton, Dickinson And Company Immuno-amplification
DK1633888T3 (da) * 2003-06-17 2009-07-13 Keygene Nv Midler og fremgangsmåde til påvisning af målnucleotidsekvenser under anvendelse af ligeringsassays med forbedrede oligonucleotidprobepar
US7914987B2 (en) 2004-06-14 2011-03-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in analyte detection using proximity probes
GB0605584D0 (en) 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
US8758991B2 (en) 2006-04-26 2014-06-24 University Of Louisville Research Foundation, Inc. Isolation of membrane vesicles from biological fluids and methods of using same
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
US8481698B2 (en) 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
GB201004292D0 (en) 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
EP2627781B1 (en) 2010-10-15 2017-02-22 Olink Bioscience AB Dynamic range methods
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
CA2835641C (en) 2011-05-11 2019-05-28 Exosome Diagnostics, Inc. Nucleic acid extraction from heterogeneous biological materials
US9745616B2 (en) * 2011-05-17 2017-08-29 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
GB201108678D0 (en) 2011-05-24 2011-07-06 Olink Ab Multiplexed proximity ligation assay
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
US9029086B2 (en) 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes
WO2014015149A2 (en) 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CA2887058C (en) 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
WO2014076209A1 (en) 2012-11-14 2014-05-22 Olink Ab Localised rca-based amplification method
WO2014076214A1 (en) 2012-11-14 2014-05-22 Olink Ab Rca reporter probes and their use in detecting nucleic acid molecules
US9086412B2 (en) 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
EP2941629B1 (en) 2013-01-03 2018-10-10 Exosome Diagnostics Inc. Methods for isolating microvesicles
AU2014305994B2 (en) 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
AU2014312211A1 (en) * 2013-08-28 2016-03-10 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105745334B (zh) 2013-09-30 2019-12-10 吴迪 通过使用邻近条形编码分析分子复合物的概况的方法
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
EP3366784B1 (en) 2014-02-28 2019-11-13 Exosome Sciences Inc. Brain specific exosome based diagnostics and extracorporeal therapies
WO2015175856A1 (en) * 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
WO2015193427A1 (en) 2014-06-19 2015-12-23 Olink Ab Determination and analysis of biomarkers in clinical samples
JP2017537657A (ja) 2014-12-11 2017-12-21 ニユー・イングランド・バイオレイブス・インコーポレイテツド 標的配列の濃縮
US11175286B2 (en) * 2015-01-09 2021-11-16 Spot Biosystems Ltd. Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles
WO2016145128A1 (en) * 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN114217058A (zh) * 2015-09-22 2022-03-22 波士顿大学董事会 纳米囊泡的多重表型分析
GB201518655D0 (en) 2015-10-21 2015-12-02 Olink Ab Method for generating proximity probes
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
JP7280823B2 (ja) * 2016-11-30 2023-05-24 エクソサム ダイアグノスティクス，インコーポレイティド 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物
WO2018119455A1 (en) 2016-12-23 2018-06-28 Exosome Diagnostics, Inc. Biofluid analysis and quantitation systems and methods
US11899024B2 (en) 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
WO2019018537A1 (en) 2017-07-18 2019-01-24 Exosome Diagnostics, Inc. NUCLEIC ACID SEQUENCING ASSOCIATED WITH EXOSOMAL ISOLATION IN PATIENTS WITH MULTIPLE GLIOBLASTOMA
WO2019022542A2 (ko) 2017-07-26 2019-01-31 ㈜로제타엑소좀 양이온을 이용한 세포밖 소포체의 분리 방법
EP3660142A4 (en) 2017-07-26 2021-05-05 Rosetta Exosome METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS
WO2019066501A1 (ko) 2017-09-27 2019-04-04 ㈜로제타엑소좀 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도
WO2019103548A2 (ko) 2017-11-24 2019-05-31 ㈜로제타엑소좀 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법
WO2019113499A1 (en) * 2017-12-07 2019-06-13 The Broad Institute, Inc. High-throughput methods for identifying gene interactions and networks
US12480940B2 (en) * 2018-05-17 2025-11-25 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
WO2019236853A1 (en) 2018-06-06 2019-12-12 Exosome Diagnostics, Inc. Methods for developing urine biomarkers and for detecting bladder cancer
WO2019238944A1 (en) 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
WO2020086751A1 (en) * 2018-10-23 2020-04-30 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
WO2020106853A1 (en) 2018-11-20 2020-05-28 Exosome Diagnostics, Inc. Compositions and methods for internal controls of microvesicle isolations
AU2020233286B2 (en) 2019-03-01 2022-10-20 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
US20230243834A1 (en) * 2020-01-17 2023-08-03 Mercy Bioanalytics, Inc. Compositions and methods for detection of ovarian cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246792A1 (en) 1999-06-17 2009-10-01 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2015188192A3 (en) 2014-06-06 2016-05-26 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
WO2017214127A1 (en) 2016-06-06 2017-12-14 Redvault Biosciences, Lp Target reporter constructs and uses thereof

Also Published As

Publication number Publication date
EP3931351A1 (en) 2022-01-05
EP3998349A3 (en) 2022-08-24
AU2022241629B2 (en) 2025-05-29
AU2020233286B2 (en) 2022-10-20
JP2022521781A (ja) 2022-04-12
EP3998349A2 (en) 2022-05-18
EP3931351B1 (en) 2024-09-11
JP7344973B2 (ja) 2023-09-14
US11085089B2 (en) 2021-08-10
EP3931351A4 (en) 2022-05-11
AU2022241629A1 (en) 2022-10-27
US20200299780A1 (en) 2020-09-24
AU2022241629C1 (en) 2026-04-09
AU2020233286A1 (en) 2021-10-14
US20210214806A1 (en) 2021-07-15
CN113748217B (zh) 2023-08-25
US20220155304A1 (en) 2022-05-19
CN113748217A (zh) 2021-12-03
SG11202109423TA (en) 2021-09-29
WO2020180741A1 (en) 2020-09-10
KR20210141952A (ko) 2021-11-23
CA3129868A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
KR102599718B1 (ko) 표적 엔티티 검출을 위한 시스템, 조성물 및 방법
KR20220129591A (ko) 난소암의 검출을 위한 조성물 및 방법
KR20230044429A (ko) 폐암의 검출을 위한 조성물 및 방법
WO2023004083A2 (en) Compositions and methods for detection of bile duct cancer
US20240377401A1 (en) Compositions and methods for detection of prostate cancer
WO2023004079A2 (en) Compositions and methods for detection of liver cancer
US20240369560A1 (en) Compositions and methods for detection of pancreatic cancer
US20240344139A1 (en) Compositions and methods for detection of colorectal cancer
HK40076883A (en) Compositions and methods for target protein detection on exosomes using proximal ligation
HK40066670B (en) Method for target entity detection using ligase
US20250327129A1 (en) Compositions and methods for detection of ovarian cancer
HK40066670A (en) Method for target entity detection using ligase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601